The Lymphoma Channel is supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
EHA 2026 | Could TME profiling help clinicians identify responses to glofitamab & other agents in DLBCL?
Thiago Maass Steiner, PhD, Peter MacCallum Cancer Centre, Melbourne, Australia, comments on the potential of tumor microenvironment (TME) profiling to predict responses to glofitamab and other therapies in diffuse large B-cell lymphoma (DLBCL). Dr Steiner highlights that while TME profiling strategies have shown promise, further research is needed to overcome the challenges of clinical application, including the need for large numbers of patient samples and longitudinal data to inform treatment decisions. This interview took place at the 31st Congress of the European Hematology Association (EHA) in Stockholm, Sweden.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
TME profiling is definitely something that has been very successful. One example is Lymphomaps, as published by Michael Green’s group last year. So we do think that similar strategies to Lymphomaps, for example, could be used to predict response to bispecific antibodies, including in the first-line setting. This research, it provides deep mechanistic insights. However, we rely too heavily on multiplex immunohistochemistry and on the localization of these different immune cells, which makes it harder for direct clinical application...
TME profiling is definitely something that has been very successful. One example is Lymphomaps, as published by Michael Green’s group last year. So we do think that similar strategies to Lymphomaps, for example, could be used to predict response to bispecific antibodies, including in the first-line setting. This research, it provides deep mechanistic insights. However, we rely too heavily on multiplex immunohistochemistry and on the localization of these different immune cells, which makes it harder for direct clinical application. But this is the goal that we can achieve to use the tumor microenvironment to predict which patients are going to respond or not to glofitamab therapy. Now, if we can use the tumor microenvironment profiling to predict whether a patient will respond to certify a patient for CAR-T cell therapy or bispecific antibodies, that’s the ultimate goal. Of course, for that, we require a large number of patient samples and longitudinal patient samples and then assess patients who don’t respond to CAR T cells and then respond to bispecific antibodies or vice versa and the reasons why they can respond to one and not to another one. But in my opinion, the most important thing will be to see where the T-cell engages will be used, will end up being used in the therapy more often. Because if they make it to the first line setting, the key question will be to understand why patients who fail bispecific antibodies also fail CAR T-cells. So it will be to identify these patients and then work out what would be the best therapy for these patients, what would be the best combination therapy for these patients.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
